Alexion ($AXLN), like many of its pharma peers, has moved some operations to Ireland to enjoy the country's low tax rate. Now, it's beefing up those operations: Thursday, the rare-disease drugmaker announced plans for its third Irish project, a new supply-chain facility that should produce around 200 jobs come 2016. More